FindTrial
Sign In

KITE-363

BIOLOGICAL4 trials

Sponsors

Kite, A Gilead Company

Conditions

Autoimmune DiseasesChronic Inflammatory Demyelinating PolyneuropathyIdiopathic Inflammatory MyopathyLupus NephritisMultiple SclerosisMyasthenia GravisRelapsed and/or Refractory B-cell LymphomaSolid and Hematological Malignancies

Phase 1

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Active, not recruitingNCT04989803
Kite, A Gilead CompanyRelapsed and/or Refractory B-cell Lymphoma
Start: 2021-10-27End: 2030-02-01Target: 247Updated: 2026-10-28
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
Enrolling by invitationNCT07038447
Kite, A Gilead CompanyIdiopathic Inflammatory Myopathy, Lupus Nephritis, Systemic Lupus Erythematosus +1
Start: 2025-07-02End: 2030-09-01Target: 52Updated: 2026-09-28
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
RecruitingNCT07304154
Kite, A Gilead CompanyChronic Inflammatory Demyelinating Polyneuropathy, Multiple Sclerosis, Myasthenia Gravis
Start: 2026-04-10End: 2029-06-01Target: 57Updated: 2026-10-19

Unknown Phase

Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
Enrolling by invitationNCT05041309
Kite, A Gilead CompanyAutoimmune Diseases, Solid and Hematological Malignancies
Start: 2021-12-15End: 2040-12-01Target: 1500Updated: 2026-09-21

Related Papers

KITE-753: A phase 2 study of an autologous anti-CD19/CD20 CAR T-cell therapy in CAR-naive patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
Journal of Clinical Oncology2026-05-28
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2
Journal of Hematology & Oncology2026-04-27
A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).
Journal of Clinical Oncology2025-05-281 citations
Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
Blood2024-11-056 citations
KITE-753: An Autologous Rapid Manufactured Anti-CD19/CD20 CAR-T Product for the Treatment of B-Cell Malignancies
Blood2024-11-051 citations
KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL).
Journal of Clinical Oncology2022-06-013 citations